Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	34.19B
Revenue (ttm)	3.14B
Net Income (ttm)	951.15M
Shares Out	406.80M
EPS (ttm)	2.33
PE Ratio	36.10
Forward PE	26.62
Dividend	0.62 (0.74%)
Ex-Dividend Date	May 9, 2025

Volume	2,319,814
Average Volume	2,352,547
Open	83.80
Previous Close	83.78
Day's Range	83.08 - 86.00
52-Week Range	65.02 - 93.52
Beta	-0.28
RSI	55.75
Earnings Date	Oct 23, 2025

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,423
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2024, Xiamen Amoytop Biotech's revenue was 2.82 billion, an increase of 34.13% compared to the previous year's 2.10 billion. Earnings were 827.60 million, an increase of 49.00%.